BioCryst Pharmaceuticals, Inc.
BCRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $451 | $331 | $271 | $157 |
| % Growth | 36% | 22.4% | 72.3% | – |
| Cost of Goods Sold | $12 | $5 | $7 | $7 |
| Gross Profit | $438 | $327 | $264 | $150 |
| % Margin | 97.2% | 98.6% | 97.6% | 95.4% |
| R&D Expenses | $175 | $217 | $253 | $209 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $266 | $214 | $159 | $119 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $441 | $430 | $413 | $328 |
| Operating Income | -$3 | -$104 | -$148 | -$178 |
| % Margin | -0.6% | -31.3% | -54.8% | -113.1% |
| Other Income/Exp. Net | -$84 | -$123 | -$96 | -$4 |
| Pre-Tax Income | -$87 | -$226 | -$244 | -$182 |
| Tax Expense | $2 | $0 | $3 | $2 |
| Net Income | -$89 | -$227 | -$247 | -$184 |
| % Margin | -19.7% | -68.4% | -91.2% | -117.1% |
| EPS | -0.43 | -1.18 | -1.33 | -1.03 |
| % Growth | 63.6% | 11.3% | -29.1% | – |
| EPS Diluted | -0.43 | -1.18 | -1.33 | -1.03 |
| Weighted Avg Shares Out | 207 | 192 | 186 | 179 |
| Weighted Avg Shares Out Dil | 207 | 192 | 186 | 179 |
| Supplemental Information | – | – | – | – |
| Interest Income | $15 | $16 | $5 | $0 |
| Interest Expense | $99 | $108 | $99 | $59 |
| Depreciation & Amortization | $1 | $2 | $1 | $1 |
| EBITDA | $13 | -$116 | -$144 | -$122 |
| % Margin | 2.8% | -35.1% | -53.1% | -77.5% |